Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||lung non-small cell carcinoma||not applicable||ALX148 + Pembrolizumab||Phase I||Actionable||In a Phase I trial, ALX148 and Keytruda (pembrolizumab) combination treatment resulted in a partial response in 4% (1/23) and stable disease in 35% (8/23) of patients with non-small cell lung cancer resistant or refractory to immune checkpoint inhibitors (J Clin Oncol 37, no. 15_suppl (May 20, 2019) 2514-2514; NCT03013218).||detail...|
|PubMed Id||Reference Title||Details|
|A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.||Full reference...|